Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy CohBar stock

Own CohBar stock in just a few minutes.

CohBar, Inc is a biotechnology business based in the US. CohBar shares (CWBR) are listed on the NASDAQ and all prices are listed in US Dollars. CohBar employs 11 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in CohBar

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CWBR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

CohBar share price

Use our graph to track the performance of CWBR stocks over time.

CohBar shares at a glance

Information last updated 2021-04-29.
52-week range$0.88 - $4.25
50-day moving average $1.36
200-day moving average $1.36
Wall St. target price$5.83
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.35

Buy CohBar shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy CohBar stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CohBar financials

Gross profit TTM $0
Return on assets TTM -46.56%
Return on equity TTM -122.18%
Profit margin 0%
Book value $0.30
Market capitalisation $80.9 million

TTM: trailing 12 months

Shorting CohBar shares

There are currently 2.9 million CohBar shares held short by investors – that's known as CohBar's "short interest". This figure is 7.9% up from 2.7 million last month.

There are a few different ways that this level of interest in shorting CohBar shares can be evaluated.

CohBar's "short interest ratio" (SIR)

CohBar's "short interest ratio" (SIR) is the quantity of CohBar shares currently shorted divided by the average quantity of CohBar shares traded daily (recently around 590587.70491803). CohBar's SIR currently stands at 4.88. In other words for every 100,000 CohBar shares traded daily on the market, roughly 4880 shares are currently held short.

However CohBar's short interest can also be evaluated against the total number of CohBar shares, or, against the total number of tradable CohBar shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CohBar's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 CohBar shares in existence, roughly 50 shares are currently held short) or 0.0604% of the tradable shares (for every 100,000 tradable CohBar shares, roughly 60 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against CohBar.

Find out more about how you can short CohBar stock.

CohBar share dividends

We're not expecting CohBar to pay a dividend over the next 12 months.

CohBar share price volatility

Over the last 12 months, CohBar's shares have ranged in value from as little as $0.875 up to $4.25. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while CohBar's is 2.8125. This would suggest that CohBar's shares are significantly more volatile than the average for this exchange and represent a higher risk.

CohBar overview

CohBar, Inc. , a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, acute respiratory distress syndrome, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site